Ross C. Donehower

Ross C. Donehower's AcademicInfluence.com Rankings

Ross C. Donehower

Philosophy

#7463

World Rank

#10683

Historical Rank

Logic

#4510

World Rank

#5819

Historical Rank

philosophy Degrees

Ross C. Donehower

Biology

#10130

World Rank

#13428

Historical Rank

Immunology

#630

World Rank

#651

Historical Rank

Molecular Biology

#1444

World Rank

#1471

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Ross C. Donehower's Degrees

Doctorate Medicine University of Pennsylvania
PhD Molecular Biology University of Pennsylvania

Why Is Ross C. Donehower Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ross C. Donehower's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) (4313)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (2015) (3718)
PD-1 blockade in tumors with mismatch repair deficiency. (2015) (2914)
Drug therapy : paclitaxel (Taxol) (1995) (1275)
Hypersensitivity reactions from taxol. (1990) (1093)
Taxol: a novel investigational antimicrotubule agent. (1990) (1057)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. (1989) (885)
Clinical toxicities encountered with paclitaxel (Taxol). (1993) (694)
The current status of camptothecin analogues as antitumor agents. (1993) (623)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. (2001) (567)
Paclitaxel (taxol) (1995) (513)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer (2013) (466)
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. (2005) (443)
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. (1988) (393)
Cardiac disturbances during the administration of taxol. (1991) (359)
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies (1994) (352)
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. (2008) (328)
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. (1991) (318)
Phase II study of erlotinib in patients with advanced biliary cancer. (2006) (300)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. (2002) (267)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. (2014) (250)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer (2010) (242)
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. (1992) (229)
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. (1994) (224)
Neurotoxicity of Taxol. (1993) (222)
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. (2001) (217)
Phase I and pharmacodynamic study of taxol in refractory acute leukemias. (1989) (207)
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. (2001) (206)
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. (2004) (198)
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. (1999) (195)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. (1993) (194)
Phase I trial of taxol in patients with advanced cancer. (1987) (184)
Interventions for preventing neuropathy caused by cisplatin and related compounds. (2011) (181)
MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (2007) (179)
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer (2000) (177)
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. (1996) (175)
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. (2002) (165)
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases (2013) (161)
An overview of the clinical experience with hydroxyurea. (1992) (156)
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2002) (155)
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. (2013) (152)
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. (1996) (151)
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. (1996) (143)
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. (1992) (131)
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. (1987) (129)
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. (1994) (125)
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. (2005) (121)
Phase I and pharmacologic study of topotecan in patients with impaired renal function. (1996) (115)
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. (2008) (115)
Successful re-treatment with taxol after major hypersensitivity reactions. (1993) (112)
Phase II study of flavopiridol in patients with advanced colorectal cancer. (2003) (108)
Development of polyploidization in taxol-resistant human leukemia cells in vitro. (1990) (107)
Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest (1989) (107)
Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. (1986) (104)
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. (1999) (104)
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer (2012) (101)
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2001) (100)
The clinical pharmacology of paclitaxel (Taxol). (1993) (99)
Clinical pharmacology of methotrexate. (1981) (98)
Programmed death-1 blockade in mismatch repair deficient colorectal cancer. (2016) (98)
Presence of 2,4‐diamino‐N10‐methylpteroic acid after high‐dose methotrexate (1979) (97)
Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. (1986) (94)
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. (1995) (87)
Tumor targeting by conjugation of DHA to paclitaxel. (2001) (87)
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. (2003) (87)
Analysis of circulating tumor DNA to confirm somatic KRAS mutations. (2009) (85)
Hepatic metabolism and biliary excretion of Taxol in rats and humans. (1993) (84)
Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) (2004) (84)
Taxol: twenty years later, the story unfolds. (1991) (83)
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. (2003) (82)
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. (1996) (82)
Taxol: pharmacology, metabolism and clinical implications. (1993) (81)
A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland (1998) (79)
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (75)
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. (2005) (74)
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. (2000) (73)
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. (2016) (71)
Interventions for preventing neuropathy caused by cisplatin and related compounds. (2014) (70)
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer (2010) (69)
An overview of experience with TAXOL (paclitaxel) in the U.S.A. (1993) (67)
Interventions for preventing neuropathy caused by cisplatin and related compounds. (2007) (65)
Competitive protein binding assay of methotrexate. (1975) (63)
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. (2008) (62)
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study (2017) (61)
A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. (2006) (58)
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. (2006) (56)
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer (2017) (56)
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer (2013) (55)
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. (2003) (55)
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. (1996) (54)
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. (1998) (54)
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. (1996) (54)
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors (2001) (52)
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma (2011) (51)
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. (1994) (50)
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. (1993) (48)
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. (1996) (48)
New developments on the mechanisms of action of antineoplastic drugs. (1979) (48)
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. (2007) (47)
Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. (2009) (45)
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. (1989) (44)
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors (2008) (44)
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine (2005) (43)
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. (2000) (41)
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. (1986) (41)
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. (1990) (40)
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. (1990) (39)
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours (2014) (39)
Should anticancer drug doses be adjusted in the obese patient? (1995) (38)
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression (2015) (38)
Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells. (1989) (38)
Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma (2004) (37)
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. (1995) (36)
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity. (1990) (35)
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data (2004) (35)
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study. (1987) (34)
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer (2019) (34)
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay (2009) (34)
Phase II trial of carboplatin in non-small cell lung cancer. (1986) (33)
The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute (1996) (32)
Hepatic toxicity of low doses of mithramycin in hypercalcemia. (1984) (31)
6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma (2011) (30)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors (2008) (30)
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. (1989) (30)
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. (2013) (30)
Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. (1978) (29)
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. (1997) (28)
Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. (1989) (28)
Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. (1987) (26)
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer (2008) (26)
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors (2018) (25)
Camptothecin analogues: studies from The Johns Hopkins Oncology Center (2004) (24)
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil. (1982) (24)
Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (2005) (24)
Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. (2004) (22)
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. (1997) (22)
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. (1982) (21)
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies (2006) (21)
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. (2013) (21)
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. (2010) (21)
Tastes associated with parenteral chemotherapy for breast cancer. (1985) (21)
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer (2017) (20)
Is HIF-1α a Valid Therapeutic Target? (2003) (20)
Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. (1980) (20)
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. (1998) (20)
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. (2019) (20)
Solitary, isolated metastasis from Ewing's sarcoma to the brain: case report. (1991) (20)
Evolving therapies: Farnesyltransferase inhibitors (2002) (19)
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer (2013) (19)
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer (2016) (19)
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. (2010) (18)
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. (1992) (17)
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. (1998) (16)
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. (1998) (16)
Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens. (1984) (15)
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. (1990) (15)
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. (1995) (15)
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. (2000) (15)
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. (1988) (14)
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study. (1989) (14)
A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. (1986) (14)
Phase I study of N-methylformamide in patients with advanced cancer. (1985) (14)
The effects of food and divided dosing on the bioavailability of oral vinorelbine (1996) (13)
Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT. (2016) (13)
Is HIF-1 alpha a valid therapeutic target? (2003) (12)
Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. (2008) (12)
A phase I study of menogaril in patients with advanced cancer. (1987) (12)
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. (2007) (11)
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. (1997) (11)
Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. (2006) (11)
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (2011) (10)
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. (1998) (10)
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. (2020) (10)
Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. (2004) (10)
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017 (2020) (9)
The practical benefits of pharmacokinetics in the use of antineoplastic agents (2004) (9)
Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer (2016) (9)
A study to assess the pharmacokinetics (PK) of a single infusion of cetuximab (IMC-C225). (2004) (8)
Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors. (2006) (8)
Tissue and tumor distribution of C-penclomedine in rats. (1996) (8)
Nifedipine and oncologic Raynaud phenomenon. (1988) (7)
HIV infection presenting as an unusually large pure yolk sac tumor of the testis. (2000) (7)
Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. (2014) (7)
A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. (2011) (7)
Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (2012) (7)
Phase I and pharmacokinetic study of hepsulfam (NSC 329680). (1991) (7)
An in vitro model to predict clinical response in adult acute myelogenous leukemia. (1987) (7)
The role of plasma level monitoring in cancer chemotherapy (1981) (7)
Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans (2002) (7)
A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer (2003) (7)
Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin. (1989) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
Metabolic conversion of methotrexate in man. (1980) (6)
Recent clinical advances with camptothecin analogues. (1995) (6)
Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer (2012) (6)
Hexamethylene bisacetamide-induced cutaneous vasculitis. (1987) (6)
Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship (2017) (6)
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (6)
Absorption, Metabolism, and Excretion of C-Temozolomide following Oral Administration to Patients with Advanced Cancer (1999) (6)
O-0011 Evaluation of Met-Pathway Biomarkers in a Phase 2 Study of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine in Gastric/Esophagogastric Junction Cancer (2012) (6)
Phase II Studies (1990) (5)
Make quality cancer survivorship care possible in the era of workforce shortage. (2010) (5)
Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism. (1984) (5)
Single-board hematology fellowship track: a 10-year institutional experience. (2018) (5)
A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC). (2017) (5)
Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer (2017) (5)
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics (2004) (5)
A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. (2019) (5)
Understanding trimetrexate toxicity. (1988) (4)
Evaluating cancer chemotherapy by infusion. (1990) (4)
Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy (2004) (4)
4 Metabolism and pharmacology of taxoids (1995) (4)
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. (2007) (4)
Clinical and pharmacologic reappraisal of dichloromethotrexate. (1988) (4)
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer. (1990) (4)
Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors (2004) (4)
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (4)
A multicenter review of gemcitabine, docetaxel, and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma. (2010) (3)
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. (2008) (3)
Safety and pharmacokinetics (PK) of T138067 (T67) administered as a weekly 3-hour infusion in subjects with hepatocellular carcinoma (HCC) in a phase 1 study. (2004) (3)
[30] Competitive protein binding assay of methotrexate (1982) (3)
A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (2011) (3)
Sequence dependent effects of methotrexate (MTX) and 5-fluoropyrimidine (5-FP) in serum-free cultures of human breast cancer (1979) (3)
Development of a canine chemotherapeutic model with ifosfamide. (1996) (2)
Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine (2001) (2)
Trainee-Led Quality Improvement Project to Improve Fertility Preservation Counseling for Patients With Cancer. (2021) (2)
Therapeutic modalities: Editorial overview (1990) (2)
A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa) (2008) (2)
Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. (2012) (2)
A multivariate model for identifying risk of early death after Pancreaticoduodenectomy(PDD) and adjuvant therapy for periampullary Adenocarcinoma(PA): importance for understanding post treatment outcomes (2002) (2)
Spotlight on Clinical Response Personalizing Cancer Treatment in the Age of Global Genomic Analyses : PALB 2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer (2011) (2)
Across the cancer continuum: A communication skills curriculum for oncology fellows. (2014) (2)
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. (2013) (2)
Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (2012) (2)
Role of oral chemotherapy in colorectal cancer. (2000) (2)
Cancer-Associated Neuropathic Pain and Paraneoplastic Syndromes (2012) (2)
Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma. (1987) (1)
Phase I-II trial of N-phosphonacetyl-L-aspartate (PALA) and 5-fluorouracil (5FU) (1981) (1)
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study (1989) (1)
516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer (2010) (1)
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. (2022) (1)
A trainee-led quality improvement project to improve fertility preservation counseling and access to fertility preservation services for persons with cancer. (2021) (1)
Taxol (T): An active new drug in ovarian epithelial cancer (OVCA) (1989) (1)
Direct Relationship of Marrow Cell Growth and 1-/?-D-Arabinofuranosy Icytosine Metabolism1 (2006) (1)
A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer. (2014) (1)
Microtubule changes and cytotoxicity produced by taxol in human ovarian cell lines (1987) (1)
430 Phase I and pharmacokinetic study of UCN-01 (U) in combination with irinotecan (I) in patients with solid tumors (2004) (1)
Durable Responses to PD-1 Blockade in Mismatch-Repair Deficient Cancers, Independent of Tissue Origin (2017) (1)
A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies 1 (2001) (1)
A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule 1 (2001) (1)
Intensified adjuvant therapy for periampullary (pancreatic, nonpancreatic) adenocarcinoma using irradiation, 5FU, mitomycin C, leucovorin and dipyridamole (J9625)-update results (2000) (0)
Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review. (2013) (0)
A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. (2011) (0)
207 A phase II study of intensified adjuvant therapy for resected pancreatic and other periampullary adenocarcinoma using radiation, 5Fu, leucovorin, dipyridamole and mitomycin-C (1999) (0)
LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT) (1999) (0)
AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma (2018) (0)
Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination (1991) (0)
Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship (2016) (0)
Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1 (2006) (0)
Hematology/medical oncology fellow responses to the initial development of an antiracism curriculum. (2021) (0)
Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors. (2013) (0)
Innovation in recruitment and curricular design for diversity, equity, and inclusion (DEI) education for hematology-oncology (HO) trainees. (2022) (0)
Evaluation of escalating doses of dichloromethotrexate (DCM) with pharmacokinetic analysis in patients with hepatocellular carcinoma and other solid tumors (1982) (0)
Glutathione gsh content glutathione s transferase gst profiles and melphalan m sensitivity in murine hematopoietic cell lines (1988) (0)
Methotrexate interaction with 5-fluorouracil and 5-fluorodeoxyuridine in serum-free cultures of human breast cancer (1978) (0)
Improving resident education on the inpatient solid tumor oncology rotation through development of an asynchronous video curriculum. (2022) (0)
Reflection rounds to facilitate resilience in hematology/medical oncology fellows. (2020) (0)
Therapeutic modalities. (1993) (0)
Evaluation of vinblastine and bleomycin as second-line therapy in advanced ovarian carcinoma (1984) (0)
Atrasentan, a n E ndothelin-Recep tor A ntagonist f or Refractory A denocarcinomas: S afety a nd P harmacokinetics (2013) (0)
366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies (2004) (0)
Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1 (2006) (0)
Resident Inpatient Curriculum for Oncology (RICO): Results of a targeted needs assessment performed in the Osler Internal Medicine Residency Program. (2022) (0)
Drug enzyme interaction in intact tumor cells (1977) (0)
Therapeutic modalities. (1991) (0)
Understanding Trimetrexate Toxicity 1 (2005) (0)
The Johns Hopkins Molecular Tumor Board Precision Oncology elective for Medical Oncology fellows. (2021) (0)
Cancer Therapy: Clinical A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (0)
EVALUATING THE IMPACT OF A MULTIDISCIPLINARY SINGLE DAY CLINIC ON THE MANAGEMENT OF PANCREATIC CANCER (2007) (0)
Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ross C. Donehower?

Ross C. Donehower is affiliated with the following schools:

Ross C. Donehower's Academic­Influence.com Rankings

Ross C. Donehower's Degrees

Why Is Ross C. Donehower Influential?

Ross C. Donehower's Published Works

Published Works

What Schools Are Affiliated With Ross C. Donehower?

Ross C. Donehower's AcademicInfluence.com Rankings